Literature DB >> 11824175

A double-blind, placebo-controlled crossover study investigating the effect of porcine secretin in children with autism.

B Corbett1, K Khan, D Czapansky-Beilman, N Brady, P Dropik, D Z Goldman, K Delaney, H Sharp, I Mueller, E Shapiro, R Ziegler.   

Abstract

OBJECTIVES: A recent patient series reported the incidental findings of improved social and language skills in 3 children with autistic spectrum disorders after the administration of secretin, a peptide hormone. However, a subsequent study did not find evidence for a drug effect. Parents are seeking treatment with secretin despite the absence of empirical investigations demonstrating amelioration in autism symptomology. In order to more precisely measure the effects of secretin, this study investigated the effect of a single intravenous dose of porcine secretin on 12 autistic children through a randomized, double-blind, placebo-controlled, crossover study. Children were assessed on objective language and on social, neuropsychological, and gastrointestinal measures to evaluate drug effects. The study was conducted over a 16-week trial. The results indicated that significant differences were not observed on the majority of the dependent variables. Statistically significant differences were observed on measures of positive affect and activity level following secretin infusion. In general, the autistic children did not demonstrate the improvements described in the initial retrospective report.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11824175     DOI: 10.1177/000992280104000604

Source DB:  PubMed          Journal:  Clin Pediatr (Phila)        ISSN: 0009-9228            Impact factor:   1.168


  9 in total

1.  In children with autism, is intravenous secretin more effective than placebo in improving social skills, communication, behaviour or global functioning?: Part A: Evidence-based answer and summary.

Authors:  Susan Petryk
Journal:  Paediatr Child Health       Date:  2004-04       Impact factor: 2.253

Review 2.  Recent Developments in Treatment Outcome Measures for Young Children With Autism Spectrum Disorder (ASD).

Authors:  Rebecca Grzadzinski; Denisse Janvier; So Hyun Kim
Journal:  Semin Pediatr Neurol       Date:  2020-03-06       Impact factor: 1.636

Review 3.  Gastrointestinal factors in autistic disorder: a critical review.

Authors:  Craig A Erickson; Kimberly A Stigler; Mark R Corkins; David J Posey; Joseph F Fitzgerald; Christopher J McDougle
Journal:  J Autism Dev Disord       Date:  2005-12

Review 4.  Advances in drug treatments for children and adolescents with autism and other pervasive developmental disorders.

Authors:  Richard P Malone; Silvia S Gratz; Mary Anne Delaney; Susan B Hyman
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 5.  Intravenous secretin for autism spectrum disorders (ASD).

Authors:  Katrina Williams; John A Wray; Danielle M Wheeler
Journal:  Cochrane Database Syst Rev       Date:  2012-04-18

Review 6.  Secretin as a treatment for autism: a review of the evidence.

Authors:  Barbara E Esch; James E Carr
Journal:  J Autism Dev Disord       Date:  2004-10

7.  Children with autistic spectrum disorders. I: comparison of placebo and single dose of human synthetic secretin.

Authors:  S E Levy; M C Souders; J Wray; A F Jawad; P R Gallagher; J Coplan; J K Belchic; M Gerdes; R Mitchell; A E Mulberg
Journal:  Arch Dis Child       Date:  2003-08       Impact factor: 3.791

Review 8.  Secretin as a neuropeptide.

Authors:  Samuel S M Ng; W H Yung; Billy K C Chow
Journal:  Mol Neurobiol       Date:  2002-08       Impact factor: 5.590

9.  Short report: Autistic gastrointestinal and eating symptoms treated with secretin: a subtype of autism.

Authors:  Stefano Pallanti; Stefano Lassi; Giampaolo La Malfa; Marco Campigli; Roberto Di Rubbo; Giulia Paolini; Valentina Cesarali
Journal:  Clin Pract Epidemiol Ment Health       Date:  2005-11-15
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.